Transcriptional CDKs as therapeutic targets in MYC-dependent cancers

转录 CDK 作为 MYC 依赖性癌症的治疗靶点

基本信息

  • 批准号:
    9106921
  • 负责人:
  • 金额:
    $ 40.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-07 至 2021-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Many human cancers depend on deregulated and overexpressed MYC for their sustained growth and proliferation, yet pharmacological inhibition of this oncogenic transcription factor has proved daunting. Recent insights into how MYC promotes the cancer cell state suggests an avenue through which its oncogenic properties could be exploited therapeutically. When overexpressed, MYC acts as a global amplifier of transcription, leading to massively upregulated expression of all actively transcribed genes. Moreover, oncogenic MYC is transcriptionally regulated by large enhancer regions, or super-enhancers (SEs), that facilitate its high-level expression and are acutely sensitive to perturbation. Given the emerging status of oncogenic MYC as a SE-associated transcriptional amplifier, we sought to selectively target the mechanisms governing its transcriptional regulation. The transcription cycle of RNA polymerase II is governed by a group of cyclin-dependent kinases (CDKs), including CDKs 7-13, with critical roles in transcription initiation and elongation. We hypothesize that inhibition of CDK7, a CDK with primary roles in transcription regulation, selectively targets MYC-overexpressing cancer cells by interfering with enhancer-promoter control of gene transcription and thus MYC-driven global transcriptional amplification. In preliminary studies, we demonstrated striking activity and selectivity by THZ1, a novel prototype covalent CDK7 inhibitor, in MYCN-amplified neuroblastoma (NB) cells compared to those without MYCN amplification. This effect was associated with inhibition of global MYCN-dependent transcriptional amplification and preferentially reduced expression of SE-associated genes, especially MYCN, without toxicity to normal tissues. To validate CDK7 inhibition as a tractable therapeutic strategy against MYCN-amplified NB, we now address three pivotal research questions. Aim 1: Will newer THZ1 analogs with improved pharmacokinetics, in combination with targeted or standard cytotoxic agents, induce durable responses in MYCN-amplified NB? Aim 2: What is the basis for the selective lethality of CDK7 inhibition in MYCN-amplified NB cells? Aim 3: What are the mechanisms of resistance to THZ1? The results we generate are expected to yield important insights into approaches that could be used to inhibit amplified MYCN function in high-risk NB, and therefore may provide a compelling rationale for the treatment of other cancers with deregulated expression of MYC family proteins, which represents the long-term goal of our research.
 描述(由申请人提供):许多人类癌症依赖于去调控和过表达的MYC来维持其生长和增殖,但对这种致癌转录因子的药理学抑制已被证明是令人生畏的。最近对MYC如何促进癌细胞状态的见解表明,通过它的致癌特性可以在治疗上加以利用。当过表达时,MYC充当转录的全局放大器,导致所有活跃转录基因的表达大量上调。此外,致癌MYC受到大型增强子区域或超级增强子(SE)的转录调节,这些区域促进其高水平表达并且对干扰非常敏感。鉴于致癌MYC作为SE相关转录放大器的新地位,我们试图选择性地靶向其转录调控机制。RNA聚合酶II的转录周期由一组细胞周期蛋白依赖性激酶(CDK)控制,包括CDK 7-13,在转录起始和延伸中起关键作用。我们假设,抑制CDK 7(一种在转录调控中起主要作用的CDK),通过干扰基因转录的增强子-启动子控制,从而干扰MYC驱动的全局转录扩增,选择性地靶向MYC过表达的癌细胞。在初步研究中,我们证明了惊人的活性和选择性THZ 1,一种新的原型共价CDK 7抑制剂,在MYCN扩增的神经母细胞瘤(NB)细胞相比,那些没有MYCN扩增。这种效应与抑制全球MYCN依赖性转录扩增和优先减少SE相关基因的表达有关,特别是MYCN,对正常组织没有毒性。为了验证CDK 7抑制作为针对MYCN扩增的NB的易处理的治疗策略,我们现在解决三个关键的研究问题。目标1:具有改善的药代动力学的新THZ 1类似物与靶向或标准细胞毒性药物组合,是否会在MYCN扩增的NB中诱导持久的反应?目的2:MYCN扩增的NB细胞中CDK 7抑制的选择性致死性的基础是什么?目的3:THZ 1的耐药机制是什么?我们产生的结果预计将产生重要的见解,可用于抑制高风险NB中MYCN功能扩增的方法,因此可能为治疗MYC家族蛋白表达失调的其他癌症提供令人信服的理由,这代表了我们研究的长期目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rani E. George其他文献

Rani E. George的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rani E. George', 18)}}的其他基金

Cell lineage as an indicator of immune response in neuroblastoma
细胞谱系作为神经母细胞瘤免疫反应的指标
  • 批准号:
    10647815
  • 财政年份:
    2022
  • 资助金额:
    $ 40.77万
  • 项目类别:
Cell lineage as an indicator of immune response in neuroblastoma
细胞谱系作为神经母细胞瘤免疫反应的指标
  • 批准号:
    10467445
  • 财政年份:
    2022
  • 资助金额:
    $ 40.77万
  • 项目类别:
Translation initiation as a therapeutic target in neuroblastoma
翻译起始作为神经母细胞瘤的治疗靶点
  • 批准号:
    10577978
  • 财政年份:
    2022
  • 资助金额:
    $ 40.77万
  • 项目类别:
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
转录 CDK 作为 MYC 依赖性癌症的治疗靶点
  • 批准号:
    9898326
  • 财政年份:
    2016
  • 资助金额:
    $ 40.77万
  • 项目类别:
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
ALK 受体酪氨酸激酶作为神经母细胞瘤的治疗靶点
  • 批准号:
    8206709
  • 财政年份:
    2011
  • 资助金额:
    $ 40.77万
  • 项目类别:
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
ALK 受体酪氨酸激酶作为神经母细胞瘤的治疗靶点
  • 批准号:
    8409812
  • 财政年份:
    2011
  • 资助金额:
    $ 40.77万
  • 项目类别:
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
ALK 受体酪氨酸激酶作为神经母细胞瘤的治疗靶点
  • 批准号:
    8785831
  • 财政年份:
    2011
  • 资助金额:
    $ 40.77万
  • 项目类别:
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
ALK 受体酪氨酸激酶作为神经母细胞瘤的治疗靶点
  • 批准号:
    8040502
  • 财政年份:
    2011
  • 资助金额:
    $ 40.77万
  • 项目类别:
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
ALK 受体酪氨酸激酶作为神经母细胞瘤的治疗靶点
  • 批准号:
    8720860
  • 财政年份:
    2011
  • 资助金额:
    $ 40.77万
  • 项目类别:
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
ALK 受体酪氨酸激酶作为神经母细胞瘤的治疗靶点
  • 批准号:
    8598861
  • 财政年份:
    2011
  • 资助金额:
    $ 40.77万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 40.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了